Escalating Dose Antigen Specific Therapy with dsDNA Injection Regulate Balance Ratio of Inflammatory Cells in Pristane-Induced Lupus Mice Model
Downloads
Afzali B, Lombardi G, Lechler R I and Lord G M 2007 The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease J Clin Exp Immunol. 148 32–46.
Akahoshi M et al 1999 Th1/Th2 balance of peripheral T helper cells in systemic lupus erythematosus. Arthritis Rheum. 42 1644–8.
Anderson P O, Manzo B A, Sundstedt A, Minaee S, Symonds A, Khalid S, Rodriguez"Cabezas M E, Nicolson K, Li S, Wraith D C and Wang P 2006 Persistent antigenic stimulation alters the transcription program in T cells, resulting in antigen-specific tolerance Eur J Immunol. 36 1374–85.
Apostolidis S A, Crispín J C and Tsokos G C 2011 IL-17-producing T cells in lupus nephritis. Lupus. 20 120-4.
Burton BR, Britton GJ, Fang H, Verhagen J, Smithers B, Sabatos-Peyton C A, Carney L J, Gough J, Strobel S, Wraith D C 2014 Sequential transcriptional changes dictate safe and effective antigen-specific immunotherapy Nat Commun. 5 4741
Campbell J D, Buckland K F, McMillan S J, Kearley J, Oldfield W L G, Stern LJ, Grönlund H, van Hage M, Reynolds C J, Boyton R J and Cobbold S P 2009 Peptide immunotherapy in allergic asthma generates IL-10–dependent immunological tolerance associated with linked epitope suppression J Exp Med.206 1535–47.
Choi J, Kim S T and Craft J 2012 The pathogenesis of systemic lupus erythematosus-an update. Curr Opin Immunol. 24 651–7.
Crispin J C and Tsokos G C 2009 Human TCR- + CD4- CD8- T cells can derive from CD8+ T cells and display an inflammatory effector phenotype J Immunol. 183 4675–81.
Crispín J C, Oukka M, Bayliss G, Cohen R A, Van Beek C A, Stillman I E, Kyttaris V C, Juang Y T and Tsokos G C 2008 Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys J Immunol. 181 8761–6.
Dolff S, Bijl M, Huitema M G, Limburg P C, Kallenberg C G M and Abdulahad W H 2011 Disturbed Th1, Th2, Th17 and Treg balance in patients with systemic lupus erythematosus Clin Immunol. 141 197–204.
El-Sayed M, Nofal E, Mokadem S Al, Makhzangy I Al, Gaballah H and Akl H 2008 Correlative study of serum Th1/Th2 cytokines levels in patients with systemic lupus erythematosus with SLEDAI. Egypt Dermatol Online J. 4
Elias K M, Laurence A, Davidson T S, Stephens G, Kanno Y, Shevach E M and O'Shea J J 2008 Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 independent signaling pathway Blood. 111 1013–20.
Fousteri G, Dave A, Bot A, Juntti T, Omid S and Von Herrath M 2010 Subcutaneous insulin B:9-23/IFA immunisation induces Tregs that control late-stage prediabetes in NOD mice through IL-10 and IFNγ Diabetologia. 53 1958–70.
Gabrysová L, Nicolson KS, Streeter HB, Verhagen J, Sabatos-Peyton CA, Morgan DJ and Wraith D J 2009 Negative feedback control of the autoimmune response through antigen-induced differentiation of IL- 10-secreting Th1 cells J Exp Med. 206 1755–67.
Guimarí£es P M et al. 2017 Cytokines in systemic lupus erythematosus: Far beyond Th1/Th2 dualism lupus: Cytokine profiles. Immunol Cell Biol. 95 824–31.
Handono K, Marisa D and Kalim H 2013 Association between the low levels of vitamin D and Treg function in systemic lupus erythematosus patients. Acta Med Indones. 45 26–31.
Huang L et al 2012 Engineering DNA Nanoparticles as Immunomodulatory Reagents that Activate Regulatory T Cells J Immunol. 188 4913–20.
Kimura A and Kishimoto T 2010 IL-6: Regulator of Treg/Th17 balance Eur J Immunol. 40 1830–5.
Larché M and Wraith D C 2005 Peptide-based therapeutic vaccines for allergic and autoimmune diseases Nat Med. 11 S69
Ma J, Yu J, Tao X, Cai L, Wang J and Zheng S G 2010 The imbalance between regulatory and IL-17-secreting CD4+ T cells in lupus patients Clin Rheumatol. 29 1251–8.
Miyake K, Akahoshi M and Nakashima H 2011 Th subset balance in lupus nephritis. J Biomed Biotechnol 2011.
Pathak S and Mohan C 2011 Cellular and molecular pathogenesis of systemic lupus erythematosus: lessons from animal models. Arthritis Res Ther. 13 241.
Plantinga M et al 2011 Conventional and monocyte-derived CD11b+ dendritic cells initiate and maintain T helper 2 cell-mediated immunity to house dust mite allergen Immunity 38 322–35.
Pusdatin Kementerian Kesehatan 2017 Situasi Lupus di Indonesia (Infodatin – Jakarta) ISSN: 2442-7569
Postal M, Peliçari K O, Sinicato N A, Marini R, Costallat L T L and Appenzeller S 2013 Th1/Th2 cytokine profile in childhood-onset systemic lupus erythematosus. Cytokine. 61 785–91.
Sawla P, Hossain A, Hahn B H, Singh R P 2012 Regulatory T cells in systemic lupus erythematosus (SLE); Role of peptide tolerance Autoimmun Rev. 11 611–4.
Schwarting A, Wada T, Kinoshita K, Tesch G and Kelley V R 1998 IFN-gamma receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Fas(lpr) mice J Immunol. 161 494–503.
Shah K, Lee W W, Lee S H, Kim SH, Kang SW, Craft J and Kang I 2010 Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus Arthritis Res Ther. 12 R53.
Singh-Jasuja H, Thiolat A, Ribon M, Boissier MC, Bessis N, Rammensee HG and Decker P 2013 The mouse dendritic cell marker CD11c is down-regulated upon cell activation through Toll-like receptor triggering Immunobiology 218 28–39
Tarzi M, Klunker S, Texier C, Verhoef A, Stapel S O, Akdis C A, Maillere B, Kay A B and Larche M 2006 Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. Clin Exp Allergy 36 465–74.
Theofilopoulos A N, Koundouris S, Kono D H and Lawson B R 2001 The role of IFN-gamma in systemic lupus erythematosus: a challenge to the Th1/Th2 paradigm in autoimmunity. Arthritis Res. 3 136–41.
Tsokos G C, Lo M S, Reis P C and Sullivan K E 2016 New insights into the immunopathogenesis of systemic lupus erythematosus Nat Rev Rheumatol. 12. 716
Wichainun R, Kasitanon N, Wangkaew S, Hongsongkiat S, Sukitawut W and Louthrenoo W 2013 Sensitivity and specificity of ANA and anti-dsDNA in the diagnosis of systemic lupus erythematosus: A comparison using control sera obtained from healthy individuals and patients with multiple medical problems. Asian Pac J Allergy Immunol. 31 292–8.
Xu D, Liu H, Komai-Koma M, Campbell C, McSharry C, Alexander J and Liew F Y 2003 CD4+CD25+ regulatory T cells suppress differentiation and functions of Th1 and Th2 cells, leishmania major infection, and colitis in mice J Immunol 170 394–9.
Yang J, Yang X, Zou H, Chu Y and Li M 2011 Recovery of the immune balance between Th17 and regulatory T cells as a treatment for systemic lupus erythematosus Rheumatology (Oxford) 50 1366–72.
Yap D Y H and Lai K N 2010 Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: From basics to recent advances. J Biomed Biotechnol. 2010.
Zhu J and Mohan C 2007 SLE 1, 2, 3⋯Genetic dissection of lupus. In: Immune Mediated Disease – From Theory to Therapy (Springer-New York)
1. As an author you (or your employer or institution) may do the following:
- make copies (print or electronic) of the article for your own personal use, including for your own classroom teaching use;
- make copies and distribute such copies (including through e-mail) of the article to research colleagues, for the personal use by such colleagues (but not commercially or systematically, e.g. via an e-mail list or list server);
- present the article at a meeting or conference and to distribute copies of the article to the delegates attending such meeting;
- for your employer, if the article is a ‘work for hire', made within the scope of your employment, your employer may use all or part of the information in the article for other intra-company use (e.g. training);
- retain patent and trademark rights and rights to any process, procedure, or article of manufacture described in the article;
- include the article in full or in part in a thesis or dissertation (provided that this is not to be published commercially);
- use the article or any part thereof in a printed compilation of your works, such as collected writings or lecture notes (subsequent to publication of the article in the journal); and prepare other derivative works, to extend the article into book-length form, or to otherwise re-use portions or excerpts in other works, with full acknowledgement of its original publication in the journal;
- may reproduce or authorize others to reproduce the article, material extracted from the article, or derivative works for the author's personal use or for company use, provided that the source and the copyright notice are indicated, the copies are not used in any way that implies JSCRTE endorsement of a product or service of any employer, and the copies themselves are not offered for sale.
All copies, print or electronic, or other use of the paper or article must include the appropriate bibliographic citation for the article's publication in the journal.
2. Requests from third parties
Although authors are permitted to re-use all or portions of the article in other works, this does not include granting third-party requests for reprinting, republishing, or other types of re-use. Requests for all uses not included above, including the authorization of third parties to reproduce or otherwise use all or part of the article (including figures and tables), should be referred to JSCRTE by going to our website at http://e-journal.unair.ac.id/index.php/JSCRTE
3. Author Online Use
- Personal Servers. Authors and/or their employers shall have the right to post the accepted version of articles pre-print version of the article, or revised personal version of the final text of the article (to reflect changes made in the peer review and editing process) on their own personal servers or the servers of their institutions or employers without permission from JSCRTE, provided that the posted version includes a prominently displayed JSCRTE copyright notice and, when published, a full citation to the original publication, including a link to the article abstract in the journal homepage. Authors shall not post the final, published versions of their papers;
- Classroom or Internal Training Use. An author is expressly permitted to post any portion of the accepted version of his/her own articles on the author's personal web site or the servers of the author's institution or company in connection with the author's teaching, training, or work responsibilities, provided that the appropriate copyright, credit, and reuse notices appear prominently with the posted material. Examples of permitted uses are lecture materials, course packs, e-reserves, conference presentations, or in-house training courses;
- Electronic Preprints. Before submitting an article to an JSCRTE, authors frequently post their manuscripts to their own web site, their employer's site, or to another server that invites constructive comment from colleagues. Upon submission of an article to JSCRTE, an author is required to transfer copyright in the article to JSCRTE, and the author must update any previously posted version of the article with a prominently displayed JSCRTE copyright notice. Upon publication of an article by the JSCRTE, the author must replace any previously posted electronic versions of the article with either (1) the full citation to the work with a Digital Object Identifier (DOI) or link to the article abstract in JSCRTE homepage, or (2) the accepted version only (not the final, published version), including the JSCRTE copyright notice and full citation, with a link to the final, published article in journal homepage.
4. Articles in Press (AiP) service
JSCRTE may choose to publish an abstract or portions of the paper before we publish it in the journal. Please contact our Production department immediately if you do not want us to make any such prior publication for any reason, including disclosure of a patentable invention.
5. Author/Employer Rights
If you are employed and prepared the article on a subject within the scope of your employment, the copyright in the article belongs to your employer as a work-for-hire. In that case, JSCRTE assumes that when you sign this Form, you are authorized to do so by your employer and that your employer has consented to the transfer of copyright, to the representation and warranty of publication rights, and to all other terms and conditions of this Form. If such authorization and consent has not been given to you, an authorized representative of your employer should sign this Form as the Author.
6. JSCRTE Copyright Ownership
It is the formal policy of JSCRTE to own the copyrights to all copyrightable material in its technical publications and to the individual contributions contained therein, in order to protect the interests of the JSCRTE, its authors and their employers, and, at the same time, to facilitate the appropriate re-use of this material by others. JSCRTE distributes its technical publications throughout the world and does so by various means such as hard copy, microfiche, microfilm, and electronic media. It also abstracts and may translate its publications, and articles contained therein, for inclusion in various compendiums, collective works, databases and similar publications
Every accepted manuscript should be accompanied by "Copyright Transfer Agreement" prior to the article publication.
